1-Pyrazolyl-5,6-Disubstituted Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1230 Peachtree Street NE, Suite 3100, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2021 Feb 5;12(3):310-311. doi: 10.1021/acsmedchemlett.1c00054. eCollection 2021 Mar 11.
Abstract
摘要
相似文献
1
1-Pyrazolyl-5,6-Disubstituted Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.
ACS Med Chem Lett. 2021 Feb 5;12(3):310-311. doi: 10.1021/acsmedchemlett.1c00054. eCollection 2021 Mar 11.
2
Novel N-Heteroaryl Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.
ACS Med Chem Lett. 2021 Mar 26;12(4):530-531. doi: 10.1021/acsmedchemlett.1c00146. eCollection 2021 Apr 8.
3
Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Sci Rep. 2016 Aug 9;6:31391. doi: 10.1038/srep31391.
4
Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.
Brain. 2022 Oct 21;145(10):3472-3487. doi: 10.1093/brain/awac176.
5
Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2.
FASEB J. 2020 Nov;34(11):14217-14233. doi: 10.1096/fj.202001046R. Epub 2020 Sep 14.
6
LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Neurobiol Dis. 2020 Oct;144:105049. doi: 10.1016/j.nbd.2020.105049. Epub 2020 Aug 13.
7
Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
Brain. 2019 Sep 1;142(9):2828-2844. doi: 10.1093/brain/awz191.
8
Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Mov Disord. 2011 Sep;26(11):2026-31. doi: 10.1002/mds.23773. Epub 2011 May 24.
9
Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
Neurobiol Dis. 2016 Oct;94:10-7. doi: 10.1016/j.nbd.2016.05.019. Epub 2016 May 31.
10
LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Mov Disord. 2017 Mar;32(3):423-432. doi: 10.1002/mds.26892. Epub 2016 Dec 2.
引用本文的文献
1
Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.
Pharmaceuticals (Basel). 2024 Dec 14;17(12):1688. doi: 10.3390/ph17121688.
本文引用的文献
1
LRRK2 at the pre-synaptic site: A 16-years perspective.
J Neurochem. 2021 Apr;157(2):297-311. doi: 10.1111/jnc.15240. Epub 2021 Feb 5.
2
New hopes for disease modification in Parkinson's Disease.
Neuropharmacology. 2020 Jul;171:108085. doi: 10.1016/j.neuropharm.2020.108085. Epub 2020 Apr 13.
3
Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.
Curr Opin Cell Biol. 2020 Apr;63:102-113. doi: 10.1016/j.ceb.2020.01.001. Epub 2020 Feb 7.
4
Immunotherapy for Parkinson's disease.
Neurobiol Dis. 2020 Apr;137:104760. doi: 10.1016/j.nbd.2020.104760. Epub 2020 Jan 21.
5
Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.
J Neurochem. 2020 Feb;152(3):273-283. doi: 10.1111/jnc.14908. Epub 2019 Nov 24.
6
Parkinson disease.
Eur J Neurol. 2020 Jan;27(1):27-42. doi: 10.1111/ene.14108. Epub 2019 Nov 27.
Zotero 插件